XNYS
ELAN
Market cap11bUSD
Oct 08, Last price
22.54USD
1D
0.81%
1Q
-9.19%
IPO
-33.90%
Name
Elanco Animal Health Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Related entities
Subsidiaries (3)
ELANCO INDIA PRIVATE LIMITED
ELANCO TIERGESUNDHEIT AG
ELANCO FINANCING (NETHERLANDS) B.V.
Key people
Michael-Bryant Hicks
Executive Vice President, General Counsel, Corporate Secretary · since 2018
David S. Kinard
Executive Vice President of Human Resources · since 2019
David A. Urbanek
Executive Vice President - Manufacturing, Quality · since 2018
Todd S. Young
Chief Financial Officer, Executive Vice President · since 2018
Jeffrey N. Simmons
President, Chief Executive Officer, Director · since 2018
Independent Director · since 2018
Independent Director · since 2019
Independent Director · since 2019
Michael J. Harrington
Independent Director · since 2018
R. David Hoover
Independent Chairman of the Board · since 2018
Independent Director · since 2018
Carl L. McMillian
Independent Director
David A. Ricks
Independent Director
Independent Director · since 2019
Independent Director
Joshua L. Smiley
Independent Director
Legal address
C/O CORPORATION SERVICE COMPANY
135 NORTH PENNSYLVANIA STREET
SUITE 1600
INDIANAPOLIS, IN 46204
US
135 NORTH PENNSYLVANIA STREET
SUITE 1600
INDIANAPOLIS, IN 46204
US
Headquarters
450 ELANCO CIRCLE
INDIANAPOLIS, IN 46221
US
INDIANAPOLIS, IN 46221
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||